Get the Stockscreener App
43.69
3.80%
1.60
Pre-market:
45.00
1.31
+3.00%
Mirum Pharmaceuticals Inc stock is traded at $43.69, with a volume of 445.16K.
It is up +3.80% in the last 24 hours and up +10.72% over the past month.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
See More
Previous Close:
$42.09
Open:
$42.11
24h Volume:
445.16K
Relative Volume:
1.19
Market Cap:
$2.10B
Revenue:
$264.38M
Net Income/Loss:
$-109.16M
P/E Ratio:
-10.17
EPS:
-4.2958
Net Cash Flow:
$-39.22M
1W Performance:
-0.52%
1M Performance:
+10.72%
6M Performance:
+72.69%
1Y Performance:
+36.11%
1-Day Range:
$41.40
$44.12
1-Week Range:
$40.80
$48.89
52-Week Range:
$23.14
$48.89
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Name
Mirum Pharmaceuticals Inc
Sector
Industry
Phone
650-667-4085
Address
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| MIRM | 43.69 | 2.10B | 264.38M | -109.16M | -39.22M | -4.2958 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Nov-13-23 | Initiated | Morgan Stanley | Overweight |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-17-23 | Resumed | Evercore ISI | Outperform |
| Sep-20-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Sep-20-21 | Initiated | JP Morgan | Overweight |
| Aug-07-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-25-20 | Initiated | Robert W. Baird | Outperform |
| Aug-12-19 | Initiated | Citigroup | Buy |
| Aug-12-19 | Initiated | Evercore ISI | Outperform |
| Aug-12-19 | Initiated | Guggenheim | Buy |
| Aug-12-19 | Initiated | ROTH Capital | Buy |
| Aug-12-19 | Initiated | Raymond James | Outperform |
View All
Mirum Pharmaceuticals Inc Stock (MIRM) Latest News
Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised - MSN
Phocas Financial Corp. Has $1.48 Million Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by First Turn Management LLC - MarketBeat
Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Down 4.6% After Insider Selling - MarketBeat
MIRM FY2024 EPS Estimate Raised by Cantor Fitzgerald - MarketBeat
Insider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Sells 2,500 Shares of Stock - MarketBeat
Mirum Pharmaceuticals SVP sells $117,752 in stock - Investing.com
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates - MSN
Analysts Are Updating Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates After Its Third-Quarter Results - Simply Wall St
HC Wainwright Has Positive Estimate for MIRM FY2024 Earnings - MarketBeat
Leerink Partnrs Has Bullish Outlook for MIRM FY2024 Earnings - MarketBeat
Mirum Pharmaceuticals Inc (MIRM) Quarterly 10-Q Report - Quartzy
Janus Henderson Group PLC's Strategic Adjustment in Mirum Pharma - GuruFocus.com
Eventide Asset Management's Strategic Reduction in Mirum Pharmac - GuruFocus.com
HC Wainwright Issues Pessimistic Estimate for MIRM Earnings - MarketBeat
Mirum Pharma to Present Key Clinical Trial Data at AASLD Liver Meeting 2024 | MIRM Stock News - StockTitan
Mirum Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Mirum shares target lifted on raised sales guidance and strong LIVMARLI sales - Investing.com Canada
How To Trade (MIRM) - Stock Traders Daily
Breaking Down Mirum Pharmaceuticals: 5 Analysts Share Their Views - Benzinga
Mirum Pharmaceuticals (NASDAQ:MIRM) Issues Quarterly Earnings Results, Beats Estimates By $0.15 EPS - MarketBeat
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q3 2024 Earnings Call Transcript - Insider Monkey
Robert W. Baird Raises Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $50.00 - MarketBeat
Mirum Pharmaceuticals stock hits all-time high of $45.28 By Investing.com - Investing.com Australia
Mirum Pharmaceuticals stock hits all-time high of $45.28 - Investing.com
Mirum Pharmaceuticals Reports Strong Q3 Sales Growth - TipRanks
MIRMMirum Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Earnings call: Mirum Pharmaceuticals reports robust Q3 2024 results - Investing.com
Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - BioSpace
Earnings call: Mirum Pharmaceuticals reports robust Q3 2024 results By Investing.com - Investing.com Australia
Mirum Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Mirum Pharmaceuticals (NASDAQ:MIRM) Sets New 52-Week HighHere's What Happened - MarketBeat
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Acquired by GSA Capital Partners LLP - MarketBeat
Mirum Pharmaceuticals earnings beat by $0.15, revenue topped estimates - Investing.com UK
Earnings Outlook For Mirum Pharmaceuticals - Benzinga
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Mirum Pharma Grants 56K Stock Options, 28K RSUs in Key Employee Retention Move | MIRM Stock News - StockTitan
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences - StockTitan
Mirum’s liver disease drug candidate gets FDA breakthrough designation - MSN
High Growth Tech Stocks In The United States To Watch - Simply Wall St
Mirum Pharmaceuticals (MIRM) Scheduled to Post Earnings on Tuesday - MarketBeat
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by AlphaCentric Advisors LLC - MarketBeat
Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 - Business Wire
Is Mirum Pharmaceuticals (NASDAQ:MIRM) Using Too Much Debt? - Simply Wall St
(MIRM) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Will Mirum Pharmaceuticals, Inc. (MIRM) Report Negative Q3 Earnings? What You Should Know - MSN
Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting - BioSpace
LIVER CIRRHOSIS MARKET TO GROW AT A SUBSTANTIAL GROWTH RATE - openPR
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Rating of "Buy" by Analysts - MarketBeat
Mirum Pharmaceuticals (MIRM): A Small-Cap Biotech with Strong Sales Growth - Insider Monkey
Mirum Pharmaceuticals Inc Stock (MIRM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
6.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):